| World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
| Journal website http://www.wjon.org |
Case Report
Volume 9, Number 4, August 2018, pages 119-122
DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC)
Table
| Trial | Arms | Phase | Population | n | Primary endpoint | Estimated primary completion date |
|---|---|---|---|---|---|---|
| AA: abiraterone acetate plus prednisone; enza: enzalutamide; mCRPC: metastatic castration-refractory prostate cancer; rPFS: radiographic progression-free survival; DDR: DNA damage repair; ORR: objective response rate; PSA: prostate-specific antigen; PFS: progression-free survival. Primary completion date: the date on which the last participant in the clinical study was examined or received an intervention to collect final data for the primary outcome measure. | ||||||
| PROfound (NCT02987543) | Olaparib AA or enza | 3 | mCRPC | 340 | rPFS | 2020 |
| Talapro-2 (NCT03395197) | Talazoparib + enza Enza + placebo | 3 | mCRPC with DDR deficiency | 352 | rPFS | 2022 |
| TRITON3 (NCT02975934) | Rucaparib AA, enza or docetaxel | 3 | mCRPC with DDR deficiency | 400 | rPFS | 2022 |
| NCT02893917 | Olaparib + cediranib Olaparib | 2 | mCRPC | 90 | rPFS | 2019 |
| BRCAAway (NCT03012321) | AA + olaparib | 2 | mCRPC with DDR deficiency | 70 | PFS | 2021 |
| Olaparib AA | ||||||
| Completed trials | ||||||
| Trial | Arms | Phase | Population | n | ORR | PFS |
| NCI 9012 (NCT01576172) | AA + veliparib AA | 2 | mCRPC | 148 | 72.4% | 14.5 m (DDR+) versus 8.0 m (WT) |
| TOPARP-A (NCT01682772) | Olaparib | 2 | mCRPC | 89 | 33% | 9.8 m (DDR+) versus 2.7 m (WT) |